Short answer
Eton Pharmaceuticals, Inc. (ETON) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $58M (up 157.9% year over year) with net income of $35M.
Q3 2026 key financials · XBRL
- Revenue
- $58M
- +157.9% YoY · +54.1% QoQ
- Net income
- $35M
- +1929.2% YoY · +204.4% QoQ
- Operating margin
- 39.7%
- Gross margin
- 76.5%
- EPS (diluted)
- $1.07
- +1437.5% YoY · +197.2% QoQ
Source: XBRL data from the Eton Pharmaceuticals, Inc. (ETON) Q3 2026 10-Q on SEC EDGAR. USD.
Eton Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $57,925, up $35,466 YoY from $22,459, driven by HEMANGEOL® acquisition and higher product sales
- Gross margin 76.5% vs 35.0% YoY, gross profit $44,301 vs $7,855
- Strongest products: ALKINDI SPRINKLE®, KHINDIVI™, INCRELEX® U.S., GALZIN®, DESMODA™, Carglumic Acid; weakest, INCRELEX® outside U.S.
- Cash $55.6M, operating cash flow $49,901, investing use $18,308 including $14,100 HEMANGEOL® rights payment
- Near-term headwinds: higher G&A, FDA fees after orphan drug exemption loss, and increased R&D investment in ASN-001 and glyburide oral suspension
Risk Factors
- No material changes identified from the 2025 10-K risk factors
- Carried-forward business risk: Unanticipated risks may materially affect operations and financial condition
- Carried-forward regulatory risk: Additional unknown risks may materially harm future results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Eton Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.